静脈内免疫グロブリン市場規模、シェア、成長分析：製品別、流通チャネル別、用途別、地域別 - 産業予測 2025～2032年

静脈内免疫グロブリン市場規模は2023年に129億米ドルと評価され、2024年の138億4,000万米ドルから2032年には243億2,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは7.3％で成長する見通しです。

静脈内免疫グロブリン（IVIG）市場は、いくつかの極めて重要な要因によって力強い成長を遂げています。高齢者人口の増加、免疫不全疾患の有病率の増加、IVIG治療オプションの幅広い受容などが顕著な要因です。さらに、出血性疾患や慢性炎症性脱髄性多発神経炎（CIDP）を患う患者層の増加により、IVIGの適応外使用が拡大しています。ヘルスケア分野への多額の投資が市場拡大をさらに後押ししています。また、自己免疫疾患やその他の病的状態の割合が増加していることも、IVIG製品に対する需要を高めており、多様なヘルスケアニーズに対応する上でIVIG製品が不可欠な役割を担っていることを浮き彫りにしています。このような力学の進展に伴い、IVIG市場は今後数年間、持続的な成長を遂げるものと思われます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

静脈内免疫グロブリン市場規模：製品別& CAGR（2025-2032）

• 市場概要
• IGG
• IGA
• IGM
• IGE
• IGD

静脈内免疫グロブリン市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 専門薬局
• その他

静脈内免疫グロブリン市場規模：用途別& CAGR（2025-2032）

• 市場概要
• 免疫不全疾患
• CIDP
• 低ガンマグロブリン血症
• 先天性エイズ
• 慢性リンパ性白血病
• 重症筋無力症
• 多巣性運動神経障害
• 免疫グロブリン
• 川崎病
• ギランバレー症候群
• その他

静脈内免疫グロブリン市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• CSL Behring（Australia）
• Grifols, S.A.（Spain）
• Octapharma AG（Switzerland）
• Kedrion S.p.A（Italy）
• Bio Products Laboratory Ltd.（United Kingdom）
• Biotest AG（Germany）
• China Biologic Products Holdings, Inc.（China）
• LFB SA（France）
• Shanghai RAAS Blood Products Co., Ltd.（China）
• ADMA Biologics, Inc.（United States）
• Sanquin Blood Supply Foundation（Netherlands）
• Kamada Ltd.（Israel）
• Emergent BioSolutions Inc.（United States）
• Hualan Biological Engineering Inc.（China）
• Green Cross Corporation（South Korea）
• Bharat Serums and Vaccines Limited（India）
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.（China）
• Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.（China）
• Guangdong Shuanglin Bio-Pharmacy Co., Ltd.（China）
• Nanjing Xinbai Pharmaceutical Co., Ltd.（China）

結論と提言

Intravenous Immunoglobulin Market size was valued at USD 12.9 billion in 2023 and is poised to grow from USD 13.84 billion in 2024 to USD 24.32 billion by 2032, growing at a CAGR of 7.3% during the forecast period (2025-2032).

The intravenous immunoglobulin (IVIG) market is witnessing robust growth driven by several pivotal factors. The rising geriatric population, increasing prevalence of immunodeficiency disorders, and broader acceptance of IVIG treatment options are notable contributors. Additionally, the off-label use of IVIG is expanding, spurred by a growing demographic of patients suffering from bleeding disorders and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Significant investments in the healthcare sector further bolster market expansion. The escalating rates of autoimmune diseases and other pathological conditions also amplify the demand for IVIG products, highlighting their essential role in meeting diverse healthcare needs. As these dynamics evolve, the IVIG market is positioned for sustained growth in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Intravenous Immunoglobulin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Intravenous Immunoglobulin Market Segments Analysis

Global Intravenous Immunoglobulin Market is segmented by Product, Distribution Channel, Application and region. Based on Product, the market is segmented into IGG, IGA, IGM, IGE and IGD. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Specialty Pharmacies and Other. Based on Application, the market is segmented into Immunodeficiency diseases, CIDP, Hypogammaglobulinemia, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal motor neuropathy, ITP, Kawasaki disease, Guillain-Barre syndrome and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Intravenous Immunoglobulin Market

The increasing adoption of intravenous immunoglobulin (IVIG) therapy as the primary treatment option for various rare immunological and neurological disorders, particularly primary immunodeficiency (PI) and related conditions, serves as a key driver for the growth of the intravenous immunoglobulin market. This widespread acknowledgment of IVIG as a first-line therapeutic approach underscores its effectiveness and vital role in the successful management of these diseases. As more healthcare providers and patients recognize the benefits of IVIG, the demand for this therapy continues to rise, further solidifying its importance in treating complex immunological conditions.

Restraints in the Intravenous Immunoglobulin Market

The financial implications associated with the diagnosis and treatment of demyelinating diseases create a substantial obstacle for the intravenous immunoglobulin (IVIG) market. One of the most pressing challenges is the escalating costs associated with IVIG therapy, which significantly hinder market growth. IVIG treatment generally requires administration every three to four weeks, resulting in roughly 12 to 16 treatment sessions per year. Given the average expenditure for IVIG is approximately USD 73.89 per gram, this leads to an estimated total annual cost of around USD 10,000. Such high prices can deter patients from accessing necessary treatments, putting further strain on market expansion.

Market Trends of the Intravenous Immunoglobulin Market

The Intravenous Immunoglobulin (IVIG) market is witnessing dynamic growth fueled by several significant trends transforming its landscape. A notable increase in IVIG utilization for neurological disorders underscores its expanding therapeutic applications beyond conventional uses, reflecting a broader acceptance in clinical settings. Furthermore, the incorporation of personalized medicine approaches into IVIG therapies is reshaping treatment protocols, aligning therapies with specific patient needs for improved outcomes. Additionally, the rise of novel immunomodulatory treatments contributes to this evolving market by introducing innovative therapeutic options, enhancing the treatment landscape, and paving the way for future advancements in patient care and immunoglobulin therapies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Intravenous Immunoglobulin Market Size by Product & CAGR (2025-2032)

• Market Overview
• IGG
• IGA
• IGM
• IGE
• IGD

Global Intravenous Immunoglobulin Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies
• Other

Global Intravenous Immunoglobulin Market Size by Application & CAGR (2025-2032)

• Market Overview
• Immunodeficiency diseases
• CIDP
• Hypogammaglobulinemia
• Congenital AIDS
• Chronic Lymphocytic Leukemia
• Myasthenia Gravis
• Multifocal motor neuropathy
• ITP
• Kawasaki disease
• Guillain-Barre syndrome
• Others

Global Intravenous Immunoglobulin Market Size & CAGR (2025-2032)

• North America (Product, Distribution Channel, Application)
  • US
  • Canada
• Europe (Product, Distribution Channel, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Distribution Channel, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Distribution Channel, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Distribution Channel, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion S.p.A (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Products Laboratory Ltd. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotest AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China Biologic Products Holdings, Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai RAAS Blood Products Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ADMA Biologics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanquin Blood Supply Foundation (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kamada Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hualan Biological Engineering Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Green Cross Corporation (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Serums and Vaccines Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guangdong Shuanglin Bio-Pharmacy Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nanjing Xinbai Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations